As of 2025-10-31, the EV/EBITDA ratio of Valeo Pharma Inc (VPH.CN) is -3.80. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. VPH.CN's latest enterprise value is 42.74 mil CAD. VPH.CN's TTM EBITDA according to its financial statements is -11.25 mil CAD. Dividing these 2 quantities gives us the above VPH.CN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 32.6x - 48.9x | 40.8x |
| Forward P/E multiples | 23.3x - 35.0x | 29.2x |
| Fair Price | (5.92) - (6.34) | (6.34) |
| Upside | -1103.0% - -1175.1% | -1174.2% |
| Date | EV/EBITDA |